Banco Santander S.A. trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 3.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 310,594 shares of the biopharmaceutical company’s stock after selling 11,523 shares during the period. Banco Santander S.A.’s holdings in Pfizer were worth $10,137,000 at the end of the most recent reporting period.
Other hedge funds have also recently added to or reduced their stakes in the company. New England Investment & Retirement Group Inc. purchased a new stake in shares of Pfizer during the first quarter worth approximately $26,000. Lion Street Advisors LLC purchased a new stake in shares of Pfizer during the first quarter worth approximately $27,000. TFO TDC LLC purchased a new stake in shares of Pfizer during the fourth quarter worth approximately $37,000. Benjamin Edwards Inc. increased its stake in Pfizer by 49.8% in the first quarter. Benjamin Edwards Inc. now owns 1,008 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 335 shares during the last quarter. Finally, Wealthcare Capital Management LLC increased its stake in Pfizer by 61.2% in the fourth quarter. Wealthcare Capital Management LLC now owns 1,069 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 406 shares during the last quarter. Hedge funds and other institutional investors own 69.91% of the company’s stock.
In other Pfizer news, SVP Jennifer B. Damico sold 2,181 shares of the firm’s stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $38.35, for a total value of $83,641.35. Following the completion of the sale, the senior vice president now owns 9,647 shares of the company’s stock, valued at $369,962.45. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Douglas M. Lankler sold 65,000 shares of the firm’s stock in a transaction on Wednesday, April 29th. The shares were sold at an average price of $37.85, for a total value of $2,460,250.00. Following the completion of the sale, the executive vice president now directly owns 135,375 shares of the company’s stock, valued at approximately $5,123,943.75. The disclosure for this sale can be found here. 0.08% of the stock is owned by company insiders.
Shares of NYSE PFE traded up $0.24 during mid-day trading on Friday, hitting $37.50. 14,885,114 shares of the company were exchanged, compared to its average volume of 22,354,300. The company has a quick ratio of 0.78, a current ratio of 1.02 and a debt-to-equity ratio of 0.56. The stock has a 50 day simple moving average of $36.51 and a 200-day simple moving average of $36.84. Pfizer Inc. has a 1-year low of $27.88 and a 1-year high of $44.56. The firm has a market cap of $206.97 billion, a price-to-earnings ratio of 13.39, a price-to-earnings-growth ratio of 2.72 and a beta of 0.71.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, April 28th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.71 by $0.09. Pfizer had a return on equity of 25.76% and a net margin of 31.17%. The firm had revenue of $12.03 billion during the quarter, compared to the consensus estimate of $11.38 billion. During the same period last year, the company earned $0.85 earnings per share. The company’s revenue for the quarter was down 8.3% on a year-over-year basis. Analysts anticipate that Pfizer Inc. will post 2.81 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 8th will be issued a dividend of $0.38 per share. This represents a $1.52 annualized dividend and a dividend yield of 4.05%. The ex-dividend date is Thursday, May 7th. Pfizer’s dividend payout ratio is presently 51.53%.
Several brokerages have commented on PFE. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $37.00 price target on shares of Pfizer in a research note on Tuesday, January 28th. Zacks Investment Research lowered shares of Pfizer from a “buy” rating to a “hold” rating and set a $40.00 price target on the stock. in a research note on Monday, May 4th. Cantor Fitzgerald reiterated a “buy” rating and issued a $53.00 price target on shares of Pfizer in a research note on Thursday, March 19th. Barclays increased their price target on shares of Pfizer from $36.00 to $37.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 29th. Finally, Mizuho reiterated a “buy” rating and issued a $42.00 price target on shares of Pfizer in a research note on Monday, May 18th. Nine analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $41.28.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
See Also: What are economic reports?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.